When assessing new techniques for use with marginalized populations, it is critical to consider costs and benefits free of unexamined biases. Anything less is discriminatory and unjust.
In reports of industry-funded studies that compared the ocular hypotensive efficacy of topical prostaglandins, conclusions in the article abstracts differed from the results of the main outcome measure 62 percent of the time.
The early diagnosis of Alzheimer disease is a boon in that it enables advance planning, but that planning process can engender conflict between respect for future-oriented autonomy and future welfare.